bismuth has been researched along with n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brechbiel, M; Kennel, SJ; Mirzadeh, S; Stabin, M; Yoriyaz, H | 1 |
| Abbas Rizvi, SM; Allen, BJ; Goozee, G; Sarkar, S | 1 |
| Allen, BJ; Brechbiel, M; Li, Y; Morgenstern, A; Perkins, AC; Qu, CF; Rizvi, SM; Smith, R; Songl, YJ | 1 |
| Brechbiel, MW; Kelly, MP; Lee, FT; Scott, AM; Smyth, FE; Tahtis, K | 1 |
| Bruchertseifer, F; Lingappa, M; Morgenstern, A; Sgouros, G; Song, H; Thompson, S | 1 |
| Champion, J; Le Du, A; Montavon, G; Morgenstern, A; Rabung, T | 1 |
6 other study(ies) available for bismuth and n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid
| Article | Year |
|---|---|
Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi.
Topics: Animals; Antibodies, Monoclonal; Bismuth; Dose-Response Relationship, Radiation; Female; Isothiocyanates; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Pentetic Acid; Radioisotopes; Radiopharmaceuticals; Yttrium Radioisotopes | 1999 |
Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
Topics: Antibodies, Monoclonal; Bismuth; Chelating Agents; DNA, Neoplasm; Humans; Immunoconjugates; Isothiocyanates; Melanoma; Nucleic Acid Synthesis Inhibitors; Pentetic Acid; Radioisotopes; Terbium; Thymidine; Time Factors; Tumor Cells, Cultured | 2000 |
In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Bismuth; Cell Line, Tumor; Humans; Isothiocyanates; Mice; Mucin-1; Mucins; Pancreatic Neoplasms; Pentetic Acid; Radioimmunotherapy; Xenograft Model Antitumor Assays | 2005 |
Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Bismuth; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Immunoglobulin Fab Fragments; Isothiocyanates; Lewis Blood Group Antigens; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Survival Rate; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |
Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
Topics: Alpha Particles; Animals; Bismuth; Female; Immunoconjugates; Isothiocyanates; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Metastasis; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Rats; Receptor, ErbB-2 | 2010 |
DTPA complexation of bismuth in human blood serum.
Topics: Animals; Bismuth; Cattle; Chelating Agents; Edetic Acid; gamma-Globulins; Humans; In Vitro Techniques; Isothiocyanates; Pentetic Acid | 2012 |